Issue 52, 2021

Development of a novel radiotheranostic platform with a DOTA-based trifunctional chelating agent

Abstract

Radiotheranostics has attracted attention as a powerful strategy for treating cancer patients with precision medicine. We designed and synthesized a novel DOTA-based trifunctional agent, ADIBO-DOTADG-ALB (ADA), which allowed compounds with targeting ligands, radiometals, and an albumin binder to be readily prepared. ADA exhibited promising properties as a theranostic platform.

Graphical abstract: Development of a novel radiotheranostic platform with a DOTA-based trifunctional chelating agent

Supplementary files

Article information

Article type
Communication
Submitted
12 Feb 2021
Accepted
26 May 2021
First published
07 Jun 2021

Chem. Commun., 2021,57, 6432-6435

Development of a novel radiotheranostic platform with a DOTA-based trifunctional chelating agent

K. Nakashima, S. Iikuni, H. Watanabe and M. Ono, Chem. Commun., 2021, 57, 6432 DOI: 10.1039/D1CC00823D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements